Like many other big pharma companies, Roche Holding AG spent 2023 looking for late-stage assets to meet their short-term needs ahead of a looming patent cliff. With several large deals now signed, the company can return to its usual approach, characterized by an interest in assets throughout the development continuum.
Key Takeaways
-
After focusing on late-stage assets in 2023, Roche is back to a more holistic approach to dealmaking.
“In 2024, we’re going to see a balance between preclinical research technologies as well as preclinical programs that are anywhere...